Advertisement

Efficacy of neoadjuvant chemoradiotherapy followed by pancreatic resection for older patients with resectable and borderline resectable pancreatic ductal adenocarcinoma

Published:October 11, 2022DOI:https://doi.org/10.1016/j.hpb.2022.10.004

      Abstract

      Background

      The benefit of preoperative treatment followed by pancreatic resection in older patients with pancreatic ductal adenocarcinoma (PDAC) remains unclear. In this retrospective analysis of prospectively collected data, we evaluated the significance and safety of preoperative treatment followed by curative resection for older PDAC patients.

      Methods

      We evaluated 122 patients with resectable and borderline resectable PDAC who received neoadjuvant chemoradiotherapy (NACRT) followed by curative resection between 2009 and 2019. Changes in the prognostic nutritional indices during NACRT, surgical outcomes, and prognosis were compared between older (≥75 years, n = 44) and younger patients (<75 years, n = 78).

      Results

      The completion rate, adverse event rate, changes in prognostic nutritional indices during NACRT, and prognosis were similar between the groups. In multivariate analysis, an elevated C-reactive protein/albumin ratio (CRP/Alb) ≥ 33.1% during NACRT (p = 0.035) and no postoperative adjuvant chemotherapy (p = 0.041) were identified as significant predictors of overall survival.

      Conclusions

      NACRT followed by pancreatic resection could be safely performed in older patients, with a similar prognosis as that of younger patients, despite an increased frequency of postoperative complications. Elevated CRP/Alb during NACRT and no postoperative adjuvant chemotherapy were poor prognostic factors for older patients.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to HPB
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Gouma D.J.
        • van Geenen R.C.
        • van Gulik T.M.
        • de Haan R.J.
        • de Wit L.T.
        • Busch O.R.
        • et al.
        Rates of complications and death after pancreaticoduodenectomy: risk factors and the impact of hospital volume.
        Ann Surg. 2000; 232: 786-795
        • DeOliveira M.L.
        • Winter J.M.
        • Schafer M.
        • Cunningham S.C.
        • Cameron J.L.
        • Yeo C.J.
        • et al.
        Assessment of complications after pancreatic surgery: a novel grading system applied to 633 patients undergoing pancreaticoduodenectomy.
        Ann Surg. 2006; 244 (discussion 7–9): 931-937
        • DiCarlo V.
        • Balzano G.
        • Zerbi A.
        • Villa E.
        Pancreatic cancer resection in elderly patients.
        Br J Surg. 1998; 85: 607-610
        • Sohn T.A.
        • Yeo C.J.
        • Cameron J.L.
        • Lillemoe K.D.
        • Talamini M.A.
        • Hruban R.H.
        • et al.
        Should pancreaticoduodenectomy be performed in octogenarians?.
        J Gastrointest Surg. 1998; 2: 207-216
        • Makary M.A.
        • Winter J.M.
        • Cameron J.L.
        • Campbell K.A.
        • Chang D.
        • Cunningham S.C.
        • et al.
        Pancreaticoduodenectomy in the very elderly.
        J Gastrointest Surg. 2006; 10: 347-356
        • Khan S.
        • Sclabas G.
        • Lombardo K.R.
        • Sarr M.G.
        • Nagorney D.
        • Kendrick M.L.
        • et al.
        Pancreatoduodenectomy for ductal adenocarcinoma in the very elderly; is it safe and justified?.
        J Gastrointest Surg. 2010; 14: 1826-1831
        • Tani M.
        • Kawai M.
        • Hirono S.
        • Ina S.
        • Miyazawa M.
        • Nishioka R.
        • et al.
        A pancreaticoduodenectomy is acceptable for periampullary tumors in the elderly, even in patients over 80 years of age.
        J Hepatobiliary Pancreat Surg. 2009; 16: 675-680
        • Hatzaras I.
        • Schmidt C.
        • Klemanski D.
        • Muscarella P.
        • Melvin W.S.
        • Ellison E.C.
        • et al.
        Pancreatic resection in the octogenarian: a safe option for pancreatic malignancy.
        J Am Coll Surg. 2011; 212: 373-377
        • Petrowsky H.
        • Clavien P.A.
        Should we deny surgery for malignant hepato-pancreatico-biliary tumors to elderly patients?.
        World J Surg. 2005; 29: 1093-1100
        • Ballarin R.
        • Spaggiari M.
        • Di Benedetto F.
        • Montalti R.
        • Masetti M.
        • De Ruvo N.
        • et al.
        Do not deny pancreatic resection to elderly patients.
        J Gastrointest Surg. 2009; 13: 341-348
        • Oguro S.
        • Shimada K.
        • Kishi Y.
        • Nara S.
        • Esaki M.
        • Kosuge T.
        Perioperative and long-term outcomes after pancreaticoduodenectomy in elderly patients 80 years of age and older.
        Langenbeck's Arch Surg. 2013; 398: 531-538
        • Utsumi M.
        • Aoki H.
        • Nagahisa S.
        • Une Y.
        • Kimura Y.
        • Watanabe M.
        • et al.
        Nutritional assessment and surgical outcomes in very elderly patients undergoing pancreaticoduodenectomy: a retrospective study.
        Surg Today. 2021; 51: 941-953
      1. National comprehensive cancer Network clinical practice guidelines in oncology pancreatic adenocarcinoma. Accessed on 3/3/2022. Available at:: http://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf.

        • Okano K.
        • Suto H.
        • Oshima M.
        • Maeda E.
        • Yamamoto N.
        • Kakinoki K.
        • et al.
        A prospective phase II trial of neoadjuvant S-1 with concurrent hypofractionated radiotherapy in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma.
        Ann Surg Oncol. 2017; 24: 2777-2784
        • Endo Y.
        • Kitago M.
        • Aiura K.
        • Shinoda M.
        • Yagi H.
        • Abe Y.
        • et al.
        Efficacy and safety of preoperative 5-fluorouracil, cisplatin, and mitomycin C in combination with radiotherapy in patients with resectable and borderline resectable pancreatic cancer: a long-term follow-up study.
        World J Surg Oncol. 2019; 17: 145
        • Nakano Y.
        • Kitago M.
        • Shinoda M.
        • Abe Y.
        • Yagi H.
        • Hibi T.
        • et al.
        Clinical predictive factors of long-term survival after curative resection of pancreatic cancer: a retrospective study.
        Cancer Med. 2017; 6: 2278-2286
        • Eguchi H.
        • Takeda Y.
        • Takahashi H.
        • Nakahira S.
        • Kashiwazaki M.
        • Shimizu J.
        • et al.
        A prospective, open-label, multicenter phase 2 trial of neoadjuvant therapy using full-dose gemcitabine and S-1 concurrent with radiation for resectable pancreatic ductal adenocarcinoma.
        Ann Surg Oncol. 2019; 26: 4498-4505
        • Versteijne E.
        • Vogel J.A.
        • Besselink M.G.
        • Busch O.R.C.
        • Wilmink J.W.
        • Daams J.G.
        • et al.
        Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer.
        Br J Surg. 2018; 105: 946-958
        • Sho M.
        • Akahori T.
        • Tanaka T.
        • Kinoshita S.
        • Nagai M.
        • Tamamoto T.
        • et al.
        Importance of resectability status in neoadjuvant treatment for pancreatic cancer.
        J Hepatobiliary Pancreat Sci. 2015; 22: 563-570
        • Boone B.A.
        • Steve J.
        • Zenati M.S.
        • Hogg M.E.
        • Singhi A.D.
        • Bartlett D.L.
        • et al.
        Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma.
        Ann Surg Oncol. 2014; 21: 4351-4358
        • Barbier L.
        • Turrini O.
        • Gregoire E.
        • Viret F.
        • Le Treut Y.P.
        • Delpero J.R.
        Pancreatic head resectable adenocarcinoma: preoperative chemoradiation improves local control but does not affect survival.
        HPB. 2011; 13: 64-69
        • Fujii T.
        • Satoi S.
        • Yamada S.
        • Murotani K.
        • Yanagimoto H.
        • Takami H.
        • et al.
        Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting.
        J Gastroenterol. 2017; 52: 81-93
        • O'Reilly E.M.
        • Perelshteyn A.
        • Jarnagin W.R.
        • Schattner M.
        • Gerdes H.
        • Capanu M.
        • et al.
        A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma.
        Ann Surg. 2014; 260: 142-148
        • Kim E.J.
        • Ben-Josef E.
        • Herman J.M.
        • Bekaii-Saab T.
        • Dawson L.A.
        • Griffith K.A.
        • et al.
        A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer.
        Cancer. 2013; 119: 2692-2700
        • Casadei R.
        • Di Marco M.
        • Ricci C.
        • Santini D.
        • Serra C.
        • Calculli L.
        • et al.
        Neoadjuvant chemoradiotherapy and surgery versus surgery alone in resectable pancreatic cancer: a single-center prospective, randomized, controlled trial which failed to achieve accrual targets.
        J Gastrointest Surg. 2015; 19: 1802-1812
        • Takahashi S.
        • Ohno I.
        • Ikeda M.
        • Konishi M.
        • Kobayashi T.
        • Akimoto T.
        • et al.
        Neoadjuvant S-1 with concurrent radiotherapy followed by surgery for borderline resectable pancreatic cancer: a phase II open-label multicenter prospective trial (JASPAC05).
        Ann Surg. 2020; 276: e510-e517
        • Katz M.H.
        • Shi Q.
        • Ahmad S.A.
        • Herman J.M.
        • Marsh Rde W.
        • Collisson E.
        • et al.
        Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: alliance for clinical trials in oncology trial A021101.
        JAMA Surg. 2016; 151e161137
        • Murphy J.E.
        • Wo J.Y.
        • Ryan D.P.
        • Jiang W.
        • Yeap B.Y.
        • Drapek L.C.
        • et al.
        Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: a Phase 2 Clinical Trial.
        JAMA Oncol. 2018; 4: 963-969
      2. Unno M, Motoi T, Matsuyama Y, Satoi S, Matsumoto I, Aosasa S, et al. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). In: 2019 ASCO annual meeting. Chicago, IL.

        • Ignacio de Ulibarri J.
        • Gonzalez-Madrono A.
        • de Villar N.G.
        • Gonzalez P.
        • Gonzalez B.
        • Mancha A.
        • et al.
        CONUT: a tool for controlling nutritional status. First validation in a hospital population.
        Nutr Hosp. 2005; 20: 38-45
        • Ahmad J.
        • Grimes N.
        • Farid S.
        • Morris-Stiff G.
        Inflammatory response related scoring systems in assessing the prognosis of patients with pancreatic ductal adenocarcinoma: a systematic review.
        Hepatobiliary Pancreat Dis Int. 2014; 13: 474-481
        • McMillan D.C.
        The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer.
        Cancer Treat Rev. 2013; 39: 534-540
        • Mei Z.
        • Shi L.
        • Wang B.
        • Yang J.
        • Xiao Z.
        • Du P.
        • et al.
        Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: a systematic review and meta-analysis of 66 cohort studies.
        Cancer Treat Rev. 2017; 58: 1-13
        • Forrest L.M.
        • McMillan D.C.
        • McArdle C.S.
        • Angerson W.J.
        • Dunlop D.J.
        Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer.
        Br J Cancer. 2004; 90: 1704-1706
        • Watanabe J.
        • Otani S.
        • Sakamoto T.
        • Arai Y.
        • Hanaki T.
        • Amisaki M.
        • et al.
        Prognostic indicators based on inflammatory and nutritional factors after pancreaticoduodenectomy for pancreatic cancer.
        Surg Today. 2016; 46: 1258-1267
        • Xie H.
        • Tang S.
        • Wei L.
        • Gan J.
        Geriatric nutritional risk index as a predictor of complications and long-term outcomes in patients with gastrointestinal malignancy: a systematic review and meta-analysis.
        Cancer Cell Int. 2020; 20: 530
        • Hirahara N.
        • Matsubara T.
        • Hayashi H.
        • Takai K.
        • Nakada S.
        • Tajima Y.
        Prognostic importance of controlling nutritional status in patients undergoing curative thoracoscopic esophagectomy for esophageal cancer.
        Am J Therapeut. 2018; 25: e524-e532
        • Lin S.
        • Fang Y.
        • Mo Z.
        • Lin Y.
        • Ji C.
        • Jian Z.
        Prognostic value of lymphocyte to monocyte ratio in pancreatic cancer: a systematic review and meta-analysis including 3338 patients.
        World J Surg Oncol. 2020; 18: 186
        • Oshima M.
        • Okano K.
        • Suto H.
        • Ando Y.
        • Kamada H.
        • Masaki T.
        • et al.
        Changes and prognostic impact of inflammatory nutritional factors during neoadjuvant chemoradiotherapy for patients with resectable and borderline resectable pancreatic cancer.
        BMC Gastroenterol. 2020; 20: 423
        • Chen Y.
        • Chen K.
        • Xiao X.
        • Nie Y.
        • Qu S.
        • Gong C.
        • et al.
        Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study.
        BMC Cancer. 2016; 16: 320
        • Oettle H.
        • Neuhaus P.
        • Hochhaus A.
        • Hartmann J.T.
        • Gellert K.
        • Ridwelski K.
        • et al.
        Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.
        JAMA. 2013; 310: 1473-1481
        • Uesaka K.
        • Boku N.
        • Fukutomi A.
        • Okamura Y.
        • Konishi M.
        • Matsumoto I.
        • et al.
        Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01).
        Lancet. 2016; 388: 248-257
      3. Brierley J.D. Gospodarowicz M.K. Wittekind C. TNM classification of malignant tumours. 8th ed. Wiley-Blackwell, Oxford, United Kingdom2016
        • Clavien P.A.
        • Barkun J.
        • de Oliveira M.L.
        • Vauthey J.N.
        • Dindo D.
        • Schulick R.D.
        • et al.
        The Clavien-Dindo classification of surgical complications: five-year experience.
        Ann Surg. 2009; 250: 187-196
        • Sulpice L.
        • Rayar M.
        • D'Halluin P.N.
        • Harnoy Y.
        • Merdrignac A.
        • Bretagne J.F.
        • et al.
        Impact of age over 75 years on outcomes after pancreaticoduodenectomy.
        J Surg Res. 2012; 178: 181-187
        • Cloyd J.M.
        • Crane C.H.
        • Koay E.J.
        • Das P.
        • Krishnan S.
        • Prakash L.
        • et al.
        Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma.
        Cancer. 2016; 122: 2671-2679
        • Yamada S.
        • Fujii T.
        • Yabusaki N.
        • Murotani K.
        • Iwata N.
        • Kanda M.
        • et al.
        Clinical implication of inflammation-based prognostic score in pancreatic cancer: Glasgow prognostic score is the most reliable parameter.
        Medicine. 2016; 95e3582
        • Liu Z.
        • Jin K.
        • Guo M.
        • Long J.
        • Liu L.
        • Liu C.
        • et al.
        Prognostic value of the CRP/alb ratio, a novel inflammation-based score in pancreatic cancer.
        Ann Surg Oncol. 2017; 24: 561-568
        • Evans D.B.
        • Rich T.A.
        • Byrd D.R.
        • Cleary K.R.
        • Connelly J.H.
        • Levin B.
        • et al.
        Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas.
        Arch Surg. 1992; 127: 1335-1339
      4. Brierley J.D. Gospodarowicz M.K. TNM classification of malignant tumours. 8th ed. Wiley-Blackwell, Oxford, UK2016